Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02504489 · ClinicalTrials.gov registry record · Phase 3
Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by BeyondSpring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 559
- Enrollment target
- 20
- Study locations
NCT02504489: Completed Phase 3 study of Non-Small Cell Lung Cancer, sponsored by BeyondSpring Pharmaceuticals.
NCT02504489 is a Phase 3 study of Non-Small Cell Lung Cancer that has completed, run by BeyondSpring Pharmaceuticals. The registered enrollment target is 559 participants, below the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02504489, a Phase 3 study of Non-Small Cell Lung Cancer, has completed, sponsored by BeyondSpring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 559 participants
- Enrollment target
- 20
- Study locations
Study Summary
To compare the overall survival of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease. Secondary purposes of the study are: * To compare overall response rate (ORR) of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease. * To compare progression free survival (PFS) of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease. * To compare incidence of Grade 4 neutropenia (absolute neutrophil count \[ANC\] \< 0.5 × 109/L) on Day 8 (+/- 1 day) of Cycle 1 of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease. * To compare 24-month and 36-month OS rate of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease.
Primary Outcome
Overall survival is defined as the time (days) from the date of randomization to the date of death due to any cause (i.e., Date of death - date of randomization +1).
Conditions Studied
Interventions
- DRUG Docetaxel + Plinabulin (DP)
- DRUG Docetaxel (D)
Study Locations (20)
California
- Pacific Cancer Medical Center, Inc. - Anaheim
- Innovative Clinical Research Institute - Whittier
Illinois
- Orchard Healthcare Research Inc. - Skokie
- Carle Cancer Center - Urbana
Michigan
- Henry Ford Hospital - Detroit
- Michigan Center of Medical Research - Farmington Hills
Ohio
- University of Cincinnati - Cincinnati
- Toledo Cancer Center - Toledo
Arizona
- Ironwood Cancer & Research Centers - Chandler
Colorado
- Memorial Health Care System - Colorado Springs
Connecticut
- Cancer Center of Central Connecticut - Plainville
Georgia
- Peachtree Hematoloy-Oncology Consultants, PC - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 559 participants |
| Start Date | 2015-12 |
| Est. Completion | 2021-05-23 |
| Phase | Phase 3 |
What the finished NCT02504489 record still lists
NCT02504489 is an interventional study that assigns participants to a tested intervention. The registered 559 participants enrollment target is mid-sized for trials with a published cap, below the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel + Plinabulin (DP) is the first listed.
NCT02504489 names 20 study sites across 16 states, led by California, Illinois, Michigan.
Frequently Asked Questions
What is clinical trial NCT02504489 about?
NCT02504489 is a clinical study titled "Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC". To compare the overall survival of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease. Secondary purposes of the study are: * To compare overall response rate ...
What is the current status of trial NCT02504489?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 559 participants. The study started on 2015-12. Estimated completion is 2021-05-23.
What conditions does trial NCT02504489 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT02504489?
The interventions under investigation include: Docetaxel + Plinabulin (DP) (DRUG), Docetaxel (D) (DRUG).
Who is sponsoring clinical trial NCT02504489?
This trial is sponsored by BeyondSpring Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02504489 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02504489's enrollment target sits among peer trials
559 64th of 454 higher than 391 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04661358 · 560 participants · Phase 3
Fenofibrate for Prevention of DR Worsening
- NCT05473871 · 560 participants · NA
Enhancing Capacity in Churches to Implement PA Programs
- NCT06001541 · 560 participants · NA
Web-based Program to Improve Self-management Among Veterans-caregiver Dyads
- NCT06246916 · 560 participants · Phase 3
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia